KOSDAQ large cap

ST Pharm

A CDMO producing oligonucleotide active ingredients, ranked among global leaders in contract manufacturing for RNA therapeutics. KOSDAQ large-cap constituent. Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.

237690.KQ Updated Jul 11, 2026 2 AI consumers· 2 recurring

Annual return · 2026-07-10'21+19.5%'22-22.5%'23-23.2%'24+41%'25+83.9%YTD-22.3%
Money in·
ST Pharm
Money out·

Financials & Segments

  • Segments · Oligonucleotide CDMO · Small-molecule API · Own drug pipeline

Revenue from

No refined links yet.

Pays to

No refined links yet.


← All companiesMarkdown · JSON

For information only, not investment advice. Content on this site is generated by AI from verified, cross-checked sources and may contain errors.

© 2026 Willow Investments, Inc.Company value-chain data · contact@willowinvt.com